nancy, we undertook a systematic review of published studies assessing the validity of ambulatory, home, and clinic BP measurement devices in pregnant women to evaluate the methodology and quality of the published validation data.
H ypertension is one of the most common medical disorders complicating pregnancy, occurring in up to 10% of pregnancies. 1 Hypertensive disorders of pregnancy include chronic hypertension, gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension. 1 Complications associated with hypertension in pregnancy include placental abruption, preterm delivery, fetal growth restriction, stillbirth, maternal death secondary to stroke and eclampsia, as well as future risk of hypertension, diabetes mellitus, and cardiovascular disease. [1] [2] [3] [4] [5] [6] Blood pressure (BP) control is recommended to help prevent maternal-fetal adverse outcomes. 1, 7 However, the optimal BP goal for pregnant women with hypertension is uncertain. 8 Prior and ongoing randomized trials are investigating the effect of more intensive BP control in pregnant women with hypertension. 7, 9 Because hemodynamic and vascular changes occur during pregnancy, guidelines recommend validating BP measurement devices in pregnant women. 10, 11 The Association for the Advancement of Medical Instrumentation (ANSI/AAMI/ISO), British Hypertension Society (BHS), and European Society of Hypertension (ESH) have published protocols to validate BP measurement devices and ensure that their accuracy is comparable to the reference standard, a mercury sphygmomanometer. [10] [11] [12] [13] [14] [15] [16] These protocols were developed to standardize the procedures for validating BP devices, 17, 18 and strict adherence to an individual protocol is necessary for accuracy and statistical validity.
Inclusion and Exclusion Criteria
Articles that assessed the validity of an upper arm brachial BP measurement device compared with a traditional mercury sphygmomanometer in pregnant women were included. Articles were excluded if they examined devices that measured BP from an anatomic site other than the upper arm, if they used intra-arterial comparisons, random-zero sphygmomanometers, or other devices as the reference standard. If studies included both pregnant and nonpregnant women, they were excluded if they did not report results for pregnant participants separately from nonpregnant participants. Commentaries, meeting abstracts, editorials, book chapters, and review articles were also excluded. There was no restriction on language.
Literature Search Strategy
The following databases were searched from inception through August 3, 2017: Ovid MEDLINE, The Cochrane Library, EMBASE, CINAHL EBSCO, ClinicalTrials.gov, and International Clinical Trials Registry Platform. The search strategies are provided in the online supplemental material (Methods in the online-only Data Supplement). To supplement the database searches, a PubMED similar articles search and a cited reference search through the ISI Web of Science were conducted using articles identified from the first set of results. The dabl Educational Trust Website (http://www.dableducational.org/) was searched manually. A manual search was also performed using the reference lists from the included articles, and from review articles produced by the Ovid MEDLINE search.
Study Selection
Article eligibility was determined by 2 investigators (N.A. Bello and J.J. Woolley) who independently reviewed the title and abstract of all identified articles. If an article appeared to meet the inclusion criteria on reviewing the abstract, the full-text version of the article was retrieved for review. In the event, the 2 investigators (N.A. Bello and J.J. Woolley) disagreed on an article's eligibility, a third investigator (D. Shimbo) resolved the discrepancy.
Data Extraction
Two reviewers (N.A. Bello and J.J. Woolley) independently abstracted all data using standardized data abstraction forms. The data extraction results were compared and discrepancies were resolved by a third investigator (D. Shimbo). Information was extracted on sample size, trimester of pregnancy, systolic and diastolic BP (SBP and DBP) at study entry, and arm circumference, as well as the validation protocol(s) used and specific procedures followed during the protocol, including details on (1) the BP device being evaluated; (2) the arm used for measurement by the device and reference; (3) the sequence of device and reference measurements; (4) the number of BP comparisons between the device and reference obtained; (5) the timing of observer comparisons (sequential versus simultaneous); and (6) final SBP and DBP validation grades for the device. The device type (ambulatory, home, clinic, and home/clinic) was based on the authors' reported description. If the authors did not specify the device type, it was categorized based on other authors' classification or the device manufacturer's specification. If an article reported the validation of >1 device, or 1 device in >1 population of pregnant women (eg, those with and without preeclampsia), the results are reported separately for each device and population. For the purposes of this systematic review, a population is defined as a unique group of pregnant women described in an article which had data on BP and validation grade. A study is defined as the testing of a BP device within a population.
Definition of SBP and DBP
SBP by auscultation is defined by convention as the first appearance of clear, repetitive sounds for at least 2 consecutive beats (K1). There has been controversy and a lack of consensus on whether K4 or K5 should be used to define DBP in pregnancy. 22 Consistent with the National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy, we chose to use K5, the point at which all Korotkoff sounds disappear, to define DBP in the current study. 23 Several articles report both K4 and K5 as DBP. In this situation, DBP is presented as K5. There were 2 studies in which only K4 was reported as DBP.
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Assessment of Methodological Quality and Protocol Violations
Adherence was assessed for each study published in articles that used protocols proposed by the AAMI (1987), BHS (original 1990 or revised 1993 version), and the ESH-international protocol (IP; original 2002 version or revised 2010 version) to perform the validation study. In addition to extracting the authors' reported SBP and DBP grade for the devices, we independently determined the SBP and DBP grades for each device using data in the published articles. Similar to the classification system used to examine BP devices in other reviews, protocol violations were adjudicated and classified as major or minor, as defined in Table S1 in the online-only Data Supplement. 18, 26, 27 In some articles, the authors report additional grades based on a second validation protocol. In this situation, we extracted the reported SBP and DBP grade for each device and independently adjudicated grades. For articles that used a nonstandard protocol to perform the validation study including 2 for which only K4 was reported for DBP, 24, 25 no grades or violations are reported.
Results
A total of 2758 articles were identified and screened for inclusion ( Figure) . Of these, 960 duplicates were excluded leaving 1798 unique articles. Another 1686 articles were excluded based on abstract review, and the remaining 112 articles were assessed for eligibility based on full-text review. Of the 112 articles, 41 met the inclusion criteria for the current analysis. 24, 25, The 41 articles included >2000 pregnant women with sample sizes ranging from 10 to 170 (Table S2 ). The majority of articles (n=18) included women in the latter 2 trimesters of pregnancy, and 10 articles included women in all trimesters. Table S3 displays the devices, sample population, reference mean BP, and mean device-reference BP difference for each article. Twelve articles 25, [32] [33] [34] [35] [36] 39, 42, 44, 50, 62, 63 described the results of device validation in >1 population of pregnant women (eg, normotensive women, hypertensive women, and women with preeclampsia).
Overall, the 41 included articles examined 28 different devices; 5 were designated by the authors as ambulatory devices (Table 1) , 5 as home devices (Table 2) , and 14 as clinic devices (Table 3) . Four devices (Omron T9P, 31 Omron MIT Elite, 33 Microlife 3BTO-A, and Omron M7 57 ) were designated as appropriate for use in both the clinic and home settings by the authors; these studies are listed in both Tables 2 and  3 . The Spacelabs 90207 ambulatory BP monitor was tested most often (n=10 articles). 30, 39, 41, 47, 53, 54, 59, [64] [65] [66] The majority of devices (n=23) examined used the oscillometric method, and the remainder of devices (n=5) used the auscultatory method. Of the 41 included articles, 31 used a standard validation protocol or a modification of one (Tables 1 through 3 
Ambulatory Devices
The devices passed validation in 6 of the 16 studies in which ambulatory BP monitoring devices were examined using a standard protocol ( 28, 38 ; 1 of the 2 studies had no protocol violations. 28 The Spacelabs 90207 passed in 3 of 10 studies; all 3 studies had at least 1 major or minor protocol violation. 39, 64 The Welch Allyn QuietTrak passed in 1 of 2 studies without a protocol violation.
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Home Devices
Of the 18 studies in which home BP measurement devices were examined using a standard protocol (Table 2) , the devices passed validation in 13 studies, 3 of which had no protocol violations, 32, 33, 35 7 had at least 1 minor violation, 32, 33, 35, 44, 63 1 had at least 1 major violation, 35 and 2 had major and minor violations. 31, 35 The Microlife WatchBP Home and the Omron MIT, and T9P passed in all studies; 2 of these 5 (40%) studies had no violations. 31, 32, 35 
Clinic Devices
Of the 24 studies in which clinic BP measurement devices were examined using a standard protocol (Table 3) , the devices passed the validation in 17 studies, 7 of which had no protocol violations, 33, 34, 36, 37 7 had at least 1 minor violation, 33, 42, 48, [55] [56] [57] 62 1 had at least 1 major violation, 36 and 2 had major and minor violations. 31, 42 Overall, among pregnant women, 61% of devices passed the stated validation protocol in at least 1 study, and 34% of those devices passed without a protocol violation (Table 4) .
Discussion
In this systematic review, we found that the majority of BP measurement devices passed a validation protocol in pregnant women, but that only one-third of these devices did so without any protocol violations. The most common major protocol violation was the inclusion of too few pregnant women when a population was examined, so that too few comparisons were obtained between the device and the reference standard. The most common minor violations were related to arm circumference and SBP and DBP ranges. Of the 11 categories of protocol violations, only 2 did not occur: the use of the same/opposite arm (major) for device and reference standard, and inclusion of at least 10 women in each of the second and third trimesters of pregnancy (minor). Although not considered a violation, in 1 article 31 the authors followed a modified BHS 1990 protocol, 16 but evaluated the results using grading criteria from the BHS 1993 protocol. 10, 15 The BHS 1993 protocol is more lenient than the 1990 BHS protocol, requiring fewer participants, examining a narrower range of BP, and requiring less stringent grading criteria to pass validation. Additionally, all studies which undertook the 1993 BHS protocol 10 reported a letter grade for SBP and DBP despite the recommendation that grading should not be attempted in special groups such as pregnant women.
Substantial hemodynamic changes occur during pregnancy, including increased blood volume, stroke volume, heart rate, and consequently cardiac output along with a decrease in peripheral vascular resistance 67, 68 Thus, guidelines recommend BP devices intended for use in pregnant women should be validated in this population. 10, 11 Accurate measurement of BP enables the timely diagnosis, monitoring, and treatment of hypertensive disorders of pregnancy. 68 However, it is important to note that although validation protocols provide reassurance that a device has been validated for use in a population, the device is not necessarily accurate in all individuals. When possible, devices should be tested against a traditional sphygmomanometer in individual patients to confirm accuracy before clinical use. Obstetric guidelines 1 suggest frequent monitoring of BP in the clinic and at home for pregnant women with poorly controlled BP and those at high risk of developing preeclampsia. Preeclampsia, the concurrent development of elevated BP after 20 weeks of gestation accompanied by proteinuria or organ dysfunction, is a significant contributor to maternalfetal morbidity and mortality. 23 In light of the evidence that the treatment of preeclampsia can reduce maternal-fetal morbidity and mortality, the US Preventive Services Task Force recently updated its preeclampsia screening guideline to recommend BP measurements be obtained during each prenatal care visit (grade B). 70, 71 Several devices have undergone validation studies (n=17) among pregnant women with preeclampsia. These included 4 studies of ambulatory BP monitors, 39,54,65 8 studies of home BP devices, 32, 33, 35, 44, 57, 63 and 5 studies of clinic BP devices. 33, 36, 42, 57, 62 Of these studies, no ambulatory device passed validation; 5 of the home devices (Microlife 3BTO-A, 63 Microlife WatchBP Home, 32 Omron M7 and MIT, 35 and Omron MIT Elite 33 ), and 3 clinic devices (Dinamap ProCare 400, 36 Omron MIT, 42 and Omron MIT Elite 33 ), the latter 2 of Normotensive (without preeclampsia) and hypertensive (with and without preeclampsia; n=33)* † … … P/P P/P … … None None When >1 protocol is listed, the first protocol is the methodology followed for the validation study and additional protocols are listed when their grading criteria were applied to the data. A indicates age; Adj, adjudicated grade; BP, blood pressure; Circ, arm circumference; comp, number of BP comparisons; DBP, diastolic blood pressure range; G, final grade; n, number of participants; NG, not able to adjudicate a grade; NR, not reported; Obs, observer measurements simultaneous/sequential; Pub, published grade; SBP, systolic blood pressure range; T, trimester; and timing, device vs mercury simultaneous/sequential. *Individual studies in the population column. †Studies that passed the primary protocol. ‡Protocol Modification: Authors state they used BHS 90 criteria to enable comparison with prior studies of Spacelabs device but fewer participants because the BHS 93 allows for ≥30. When >1 protocol is listed, the first protocol is the methodology followed for the validation study and additional protocols are listed when their grading criteria were applied to the data. A indicates age; Adj, adjudicated grade; BP, blood pressure; Circ, arm circumference; comp, number of BP comparisons; DBP, diastolic blood pressure range; G, final grade; n, number of participants; NG, not able to adjudicate a grade; NR, not reported; Obs, observer measurements simultaneous/sequential; Pub, published grade; SBP, systolic blood pressure range; T, trimester; and timing, device vs mercury simultaneous/sequential. *Authors state device can be used for home or clinical use (data is also found in Table 3 ). †Protocol modification: BHS 90 protocol cited in references, but BHS 93 grading was used. ‡Individual studies in the population column. §Studies that passed the primary protocol. #Two devices, the MIT and M7, were tested in the same group of women. The MIT can accommodate an arm circumference of 22-32 cm and the M7 can accommodate up to 42 cm. Only women with an arm circumference of 22-32 cm were included in the validation studies.
¶Authors do not specify device type, so prior authors' designation followed (data is also found in Table 3 ). ║Protocol modification: BHS 90 protocol was followed but BHS 93 grading was used. which are also recommended for home use, passed the validation criteria. None of the 17 studies testing ambulatory, home, or clinic BP devices among pregnant women with preeclampsia was performed without a protocol violation. The finding that many studies wherein devices were validated had protocol violations is consistent with published studies conducted in nonpregnant women and men. 18, 27, 72, 73 In a systematic review of BP devices validated using the ESH-IP, Stergiou et al 18 found protocol violations in 23 of 78 studies. Similarly, Hodgkinson et al 27 found that of 28 validation studies of ambulatory devices performed in a general adult population, 42%, 11%, and 0% that followed the ESH-IP, AAMI, and BHS, respectively, adhered to the specified protocol without violations. The proper execution of a BP device validation study with strict adherence to the specified protocol is a complex undertaking with several opportunities for violation which may lead to improper performance and result in a detrimental effect on the study's power. 74 All violations, whether classified as major or minor, 18, 27 have the potential to effect the results of a validation study, and when noted the results of a validation study should be interpreted with caution.
Standardized validation protocols (AAMI, BHS, and ESH-IP) were developed to demonstrate statistical equivalence between new devices and the gold standard mercury sphygmomanometer. 19 Although the ESH-IP was designed to simplify validation studies and has been the most widely used protocol since 2006 among nonpregnant women and men, 18 some have questioned whether it is sufficiently powered to demonstrate equivalence. 18, 19 In the current systematic review, 3 articles (testing 4 devices) 28, 57, 58 used the ESH-IP as the primary validation protocol. The BPLab ambulatory monitor 28 was the only 1 of the 4 devices to pass the ESH-IP in pregnant women. The Microlife 3BTO-A, Omron M7, and Welch Allyn Vital Signs 300 failed the ESH-IP validation. 57, 58 Ongoing efforts by an AAMI-ESH-ISO collaboration to create a standardized sufficiently powered universal protocol that will replace all previous protocols should simplify the performance and analysis of future device validation studies among both nonpregnant and pregnant populations. 74 A strength of the current study is the use of a comprehensive search strategy of multiple databases and websites and the manual review of reference lists of all included articles, without limitations on language. Additionally, we evaluated the available validation data on ambulatory, home, and clinic devices. Data from systematic reviews of the validation of BP devices in pregnant women are sparse, and the results of our study address important knowledge gaps in this area. When >1 protocol is listed, the first protocol is the methodology followed for the validation study and additional protocols are listed when their grading criteria were applied to the data. A indicates age; Adj, adjudicated grade; BP, blood pressure; Circ, arm circumference; comp, number of BP comparisons; DBP, diastolic blood pressure range; G, final grade; n, number of participants; NG, not able to adjudicate a grade; NR, not reported; Obs, observer measurements simultaneous/sequential; Pub, published grade; SBP, systolic blood pressure range; T, trimester; and timing, device vs mercury simultaneous/sequential. *Individual studies in the population column. †Studies that passed the primary protocol. ‡Authors state device can be used for home or clinical use (data is also found in Table 2 ). §Authors do not specify device type, so prior authors' designation followed (data is also found in Table 2 ). ║Protocol Modification: BHS 90 protocol cited in references, but BHS 93 grading was used. ¶Protocol Modification: BHS 90 protocol was followed, but BHS 93 grading was used. However, the current review has several known and potential limitations. First, we excluded studies (n=18) that used a reference device other than a standard mercury sphygmomanometer (Table S4) . Although this approach may exclude potentially important studies, the majority of validation protocols require mercury sphygmomanometer as the reference standard, 10, 11, 15, 16 with the exception being the ANSI/AAMI/ ISO which has an alternative direct intra-arterial reference option.
12-14 Second, we cannot exclude the possibility of publication bias. Although we found many published studies describing device validation failures, there may be situations in which validation failures were not published. Additionally, although several studies tested the same device, we did not attempt to perform a meta-analysis because of the small number of studies in which these devices were validated without protocol violations. Last, for the 11 studies that followed a nonstandard validation protocol, 24, 25, 29, 30, [49] [50] [51] [52] [53] we were unable to adjudicate grades or assess violations and cannot comment on the validity of the devices examined. The majority of devices included in this review were oscillometric and use proprietary algorithms to calculate SBP and DBP. Without knowledge of the algorithms, further evaluation of the strengths and weaknesses of the performance of an individual device compared with another is limited.
Perspectives
In the current systematic review, a majority of validation studies examining BP measurement devices in pregnancy had violations. Of the 28 devices examined, 2 ambulatory devices (BP Lab 28 and Welch Allyn QuietTrak 60 ), 2 home devices (Microlife WatchBP Home 32 and Omron MIT 35 ), 4 clinic BP devices (A&D UM-101, 34 Dinamap ProCare 400, 36 Nissei DS-400, 37 and Omron HEM907 34 ), and 1 home/clinic device (Omron MIT Elite 33 ) passed a validation study in at least 1 population of pregnant women without any protocol violations. As results from validation studies not adhering to the protocol specifications or those without sufficient power cannot be assumed to be valid, future validation studies of devices in pregnant women are needed to ensure the accurate measurement of BP in pregnancy. Given the potential consequences of inaccurate BP measurement in pregnant women, healthcare providers should use BP devices that have been proven accurate and valid in this population.
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